INMB Q2 2021 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$7M

Net Income

-$7M

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$769,000

Balance Sheet

Total Assets

$61M

Total Liabilities

$17M

Stockholders' Equity

$43M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$7M	-$2M	-211.0%
Net Income	-$7M	-$2M	-215.7%